Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX ABIVAX Société Anonyme	$6.75 -5.2%	$6.59	$4.77 ▼ $15.06	$428.08M	0.29	132,859 shs	164,631 shs
AMLX Amylyx Pharmaceuticals	$4.65 -9.7%	$3.92	$1.58 ▼ $7.27	$414.24M	-0.6	1.23 million shs	1.23 million shs
EDIT Editas Medicine	$1.33 -13.6%	$1.41	$0.91 ▼ $6.69	$111.33M	2.14	2.58 million shs	1.77 million shs
SAGE Sage Therapeutics	$6.86 -4.3%	$7.54	$4.62 ▼ $13.47	$429.58M	0.2	1.22 million shs	1.57 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX ABIVAX Société Anonyme	-0.97%	-1.93%	+33.83%	+20.88%	-51.03%
AMLX Amylyx Pharmaceuticals	-3.20%	+2.79%	+50.15%	+42.27%	+153.69%
EDIT Editas Medicine	-6.10%	-2.53%	+49.51%	+19.38%	-72.84%
SAGE Sage Therapeutics	-1.78%	-7.72%	+4.52%	-0.97%	-48.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX ABIVAX Société Anonyme	2.3494 of 5 stars	3.5	3.0	0.0	2.8	0.8	0.6
AMLX Amylyx Pharmaceuticals	3.1165 of 5 stars	3.4	1.0	0.0	3.3	4.2	1.3
EDIT Editas Medicine	4.2337 of 5 stars	3.2	3.0	4.2	3.2	1.7	1.3
SAGE Sage Therapeutics	4.3238 of 5 stars	4.0	2.0	4.0	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX ABIVAX Société Anonyme	3.00	Buy	$34.00	403.70% Upside
AMLX Amylyx Pharmaceuticals	2.86	Moderate Buy	$8.00	72.04% Upside
EDIT Editas Medicine	2.31	Hold	$6.54	391.61% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.81	28.46% Upside

Current Analyst Ratings Breakdown

Latest EDIT, ABVX, SAGE, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	ABVX ABIVAX Société Anonyme	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/7/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $7.00
3/20/2025	ABVX ABIVAX Société Anonyme	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$12.00
3/11/2025	SAGE Sage Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$5.00
3/5/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
2/12/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$14.00 ➝ $12.00
2/12/2025	SAGE Sage Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$6.00 ➝ $6.00

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	$3.37 per share	N/A
AMLX Amylyx Pharmaceuticals	$87.37M	4.74	$0.84 per share	5.51	$6.42 per share	0.72
EDIT Editas Medicine	$32.31M	3.45	N/A	N/A	$4.27 per share	0.31
SAGE Sage Therapeutics	$47.40M	9.06	N/A	N/A	$7.56 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX ABIVAX Société Anonyme	-$159.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	$49.27M	-$4.44	N/A	N/A	N/A	N/A	-36.97%	-29.61%	5/8/2025 (Estimated)
EDIT Editas Medicine	-$153.22M	-$2.88	N/A	N/A	N/A	-340.96%	-80.13%	-50.99%	5/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-971.50%	-68.18%	-60.84%	N/A

Latest EDIT, ABVX, SAGE, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	EDIT Editas Medicine	-$0.52	N/A	N/A	N/A	$0.79 million	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/5/2025	Q4 2024	EDIT Editas Medicine	-$0.39	-$0.55	-$0.16	-$0.55	$37.17 million	$30.60 million
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million
2/11/2025	Q4 2024	SAGE Sage Therapeutics	-$1.54	-$1.56	-$0.02	-$1.56	$14.37 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	$1.02	21.85%	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX ABIVAX Société Anonyme	0.48	3.04	N/A
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
EDIT Editas Medicine	N/A	3.75	3.75
SAGE Sage Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX ABIVAX Société Anonyme	47.91%
AMLX Amylyx Pharmaceuticals	95.84%
EDIT Editas Medicine	71.90%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
ABVX ABIVAX Société Anonyme	N/A
AMLX Amylyx Pharmaceuticals	11.70%
EDIT Editas Medicine	1.90%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX ABIVAX Société Anonyme	61	63.42 million	N/A	Not Optionable
AMLX Amylyx Pharmaceuticals	200	89.08 million	60.53 million	Optionable
EDIT Editas Medicine	230	83.71 million	80.98 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	58.10 million	Optionable

EDIT, ABVX, SAGE, and AMLX Headlines

Recent News About These Companies

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

May 6 at 10:00 AM | accessnewswire.com

Trinity Life Sciences Announces Winners of TGaS Advisors Best of Benchmark Awards for Operational Excellence in Pharma Industry

May 6 at 9:07 AM | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

May 4 at 10:00 AM | accessnewswire.com

HC Wainwright Issues Optimistic Estimate for SAGE Earnings

May 4 at 7:15 AM | marketbeat.com

Wedbush Equities Analysts Raise Earnings Estimates for SAGE

May 4 at 7:15 AM | marketbeat.com

Susquehanna Fundamental Investments LLC Invests $1.17 Million in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 4 at 4:28 AM | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by StockNews.com

May 4 at 4:19 AM | americanbankingnews.com

Wedbush Research Analysts Lift Earnings Estimates for SAGE

May 4 at 1:19 AM | americanbankingnews.com

Q2 EPS Estimate for Sage Therapeutics Raised by Analyst

May 4 at 1:19 AM | americanbankingnews.com

Brokers Issue Forecasts for SAGE Q1 Earnings

May 3 at 8:36 AM | marketbeat.com

Caligan Partners LP Makes New Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 3 at 7:44 AM | marketbeat.com

PDT Partners LLC Buys 63,804 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 3 at 6:00 AM | marketbeat.com

Analysts Set Expectations for SAGE Q1 Earnings

May 2, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Estimates By $0.01 EPS

May 1, 2025 | marketbeat.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 1, 2025 | accessnewswire.com

Q1 2025 SAGE Therapeutics Inc Earnings Call

May 1, 2025 | finance.yahoo.com

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

May 1, 2025 | finance.yahoo.com

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

April 30, 2025 | zacks.com

Virtus ETF Advisers LLC Buys 33,029 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

April 30, 2025 | marketbeat.com

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

April 29, 2025 | seekingalpha.com

What to Expect from Sage Therapeutics's Earnings

April 29, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT, ABVX, SAGE, and AMLX Company Descriptions

ABIVAX Société Anonyme NASDAQ:ABVX

$6.76 -0.36 (-4.99%)

As of 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.65 -0.50 (-9.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.95 +0.30 (+6.45%)

As of 07:24 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Editas Medicine NASDAQ:EDIT

$1.33 -0.21 (-13.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.05 (+3.76%)

As of 07:57 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sage Therapeutics NASDAQ:SAGE

$6.86 -0.31 (-4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$7.16 +0.30 (+4.37%)

As of 07:48 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time